McLaren M6A

AMD Reimagines Cloud Performance with 4th Gen AMD EPYC Processors with AWS

Retrieved on: 
Tuesday, June 13, 2023

SANTA CLARA, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Today, during the “Data Center and AI Technology Premiere,” AMD (NASDAQ: AMD) announced a continuation of its relationship with Amazon Web Services (AWS) with a preview of the next generation Amazon Elastic Compute Cloud (Amazon EC2) M7a instances, powered by 4th Gen AMD EPYC™ processors.

Key Points: 
  • SANTA CLARA, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Today, during the “ Data Center and AI Technology Premiere ,” AMD (NASDAQ: AMD) announced a continuation of its relationship with Amazon Web Services (AWS) with a preview of the next generation Amazon Elastic Compute Cloud (Amazon EC2) M7a instances , powered by 4th Gen AMD EPYC™ processors.
  • “AWS has worked with AMD since 2018 to offer Amazon EC2 instances to customers.
  • “When we combine the performance of 4th Gen AMD EPYC processors with the AWS Nitro System, we’re advancing cloud technology for our customers by allowing them to do more with better performance on even more Amazon EC2 instances.”
    “AMD and AWS are reimagining what’s possible with cloud performance, driving a differentiated offering for customers with the next generation of Amazon EC2 instances,” said Dan McNamara, senior vice president, general manager, EPYC Business, AMD.
  • “We continue to showcase the immense capabilities of the world’s best data center CPU, the 4th Gen AMD EPYC processors, and our ongoing collaboration with AWS highlights the momentum and demand for EPYC to power faster applications enabling customers to bring a broader range of workloads to the cloud.”
    The new Amazon EC2 M7a instances, using 4th Gen AMD EPYC processors are now available in preview.

Eclipsebio Expands Intellectual Property Portfolio to Support New Product Suites Designed to Probe RNA Structure and Reveal Ribosome Occupancy and RNA Modifications

Retrieved on: 
Tuesday, September 27, 2022

This IP supports three key product suites, m6A-eCLIP for profiling m6A modifications, SHAPE for RNA structure probing, and Aurora for ribosome profiling.

Key Points: 
  • This IP supports three key product suites, m6A-eCLIP for profiling m6A modifications, SHAPE for RNA structure probing, and Aurora for ribosome profiling.
  • "This expansion of Eclipsebio's intellectual property portfolio supports the company's development of high-resolution, multi-dimensional RNA genomics technologies and product suites," said Peter Chu, Ph.D., CEO and cofounder of Eclipsebio.
  • Data derived from SHAPE RNA structure probing yields information that helps guide a more accurate RNA fold, an important parameter in developing RNA therapeutics.
  • For ribosome profiling, Eclipsebio is launching the Aurora products to provide a means of accurately quantifying ribosome occupancy and mapping ribosome position on mRNAs in cells.

Eclipsebio to Present Data and Unveil Antibody Barcode CLIP, a Novel Multiplexed CLIP Technology, at the RNA Society Annual Meeting 2022

Retrieved on: 
Tuesday, May 24, 2022

SAN DIEGO, May 24, 2022 /PRNewswire/ -- Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the presentation of data describing a novel multiplexed cross-linking immunoprecipitation (CLIP) technology, called Antibody Barcode CLIP, at the 27th Annual Meeting of the RNA Society taking place May 31st to June 5th in Boulder, Colorado.

Key Points: 
  • SAN DIEGO, May 24, 2022 /PRNewswire/ -- Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the presentation of data describing a novel multiplexed cross-linking immunoprecipitation (CLIP) technology, called Antibody Barcode CLIP, at the 27th Annual Meeting of the RNA Society taking place May 31st to June 5th in Boulder, Colorado.
  • This presentation will describe the successful multiplexing of 10 CLIP-like assays in a single tube, enabling the interrogation of multiple RBPs simultaneously.
  • "We plan to offer Antibody Barcode CLIP kits and services to make this technology accessible to the RNA researchers in both academia and industry."
  • The company offers its end-to-end RNA genomics products as services and kits, and also provides custom RNA genomics services for select partners.

AMD Continues Driving High Performance Cloud Computing with the New Amazon EC2 C6a Instance

Retrieved on: 
Wednesday, February 16, 2022

SANTA CLARA, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced the expansion of Amazon Web Services Inc. (AWS) AMD EPYC processor-based offerings with the general availability of compute optimized Amazon EC2 C6a instances.

Key Points: 
  • SANTA CLARA, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced the expansion of Amazon Web Services Inc. (AWS) AMD EPYC processor-based offerings with the general availability of compute optimized Amazon EC2 C6a instances.
  • This is the second AWS EC2 instance type powered by 3rd Gen AMD EPYC processors, following the release of the M6a instances.
  • These instances continue the collaboration between AWS and AMD providing AWS EC2 customers access to the performance and price performance capabilities of the latest generation of AMD EPYC processors.
  • Amazon EC2 C6a instances, powered by 3rd Gen AMD EPYC processors, continue our collaboration with AMD, providing customers the ability to run compute intensive workloads, said David Brown, Vice President, Amazon EC2, AWS.

AMD EPYC™ Processor Offerings Continue to Grow at AWS With New Instances for General Purpose Compute

Retrieved on: 
Tuesday, November 30, 2021

SANTA CLARA, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced Amazon Web Services, Inc. (AWS) has expanded its AMD EPYC™ processor-based offerings with the general availability of general-purpose Amazon EC2 M6a instances. The M6a instances are powered by 3rd Gen AMD EPYC processors delivering, according to AWS, up to 35% better price-performance compared to the previous M5a instances and a 10% lower cost than comparable x86-based EC2 instances.

Key Points: 
  • SANTA CLARA, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced Amazon Web Services, Inc. (AWS) has expanded its AMD EPYC processor-based offerings with the general availability of general-purpose Amazon EC2 M6a instances .
  • The M6a instances are powered by 3 rd Gen AMD EPYC processors delivering, according to AWS, up to 35% better price-performance compared to the previous M5a instances and a 10% lower cost than comparable x86-based EC2 instances .
  • Our 3rd Gen AMD EPYC processors provide Amazon EC2 users excellent scalability and impressive price-performance compared to previous generation Amazon EC2 M5a instances.
  • The Amazon EC2 M6a instances are the first EC2 instances powered by 3rd Gen AMD EPYC CPUs, which are to be followed by additional instances going forward.

Genetic Mutations in Digestive Cancers

Retrieved on: 
Tuesday, September 28, 2021

WASHINGTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 246, Issue 18, September 2021 ) examines genetic mutations in digestive cancers.The study, led by Dr. Yinchi Yang, in the Department of General Surgery of the Beijing Friendship Hospital at the Capital Medical University in Beijing (China), reports that regulators of mRNA modification exhibit extensive genetic modification in digestive cancers.

Key Points: 
  • WASHINGTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 246, Issue 18, September 2021 ) examines genetic mutations in digestive cancers.The study, led by Dr. Yinchi Yang, in the Department of General Surgery of the Beijing Friendship Hospital at the Capital Medical University in Beijing (China), reports that regulators of mRNA modification exhibit extensive genetic modification in digestive cancers.
  • Digestive system cancers are common throughout the world and result in over 2.5 million fatalities annually.Digestive cancers include tumors of the stomach, rectum, esophagus, colon, liver, bile duct and pancreas.
  • If caught at an early stage, treatment for digestive cancers can be effective.
  • Zhang said, "similarities and differences in the mechanisms of action of m6A regulators in the progression of digestive tract and digestive gland tumors could direct drug development."